TargetMol

JQ-1 (carboxylic acid)

Product Code:
 
TAR-T5443
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T5443-5mg5mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-1mL1 mL * 10 mM (in DMSO)£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-25mg25mg£169.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-50mg50mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-100mg100mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5443-200mg200mg£369.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
JQ-1 carboxylic acid is a cell-permeable BRD4 inhibitor with IC50s of 77 nM for BRD4(1) and 33 nM for BRD4(2)
CAS:
202592-23-2
Formula:
C19H17ClN4O2S
Molecular Weight:
400.88
Pathway:
Chromatin/Epigenetic
Purity:
0.9939
SMILES:
Cc1nnc2[C@H](CC(O)=O)N=C(c3c(C)c(C)sc3-n12)c1ccc(Cl)cc1
Target:
Epigenetic Reader Domain

References

Rosner M , Hengstschl?Ger M . Targeting Epigenetic Readers in Cancer[J]. New England Journal of Medicine, 2012, 367(18):1764-1765. Dawson M A , Prinjha R K , Dittmann A , et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia[J]. Nature, 2011, 478(7370):529-533. Mertz J A , Conery A R , Bryant B M , et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains[J]. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108(40):16669-16674.